3B Blackbio Dx Limited
NSE: 3BBLACKBIOMarket Closed • NSE
Day range
52 week range
3B Blackbio Dx Limited closed at INR1446.40 (-0.69%) on volume 0.3x its 20-day average, trading 16.87% below its 52-week high.
2026-Q2
Q2 FY2026 Financial Results
PAT moved -8.5% QoQ
2026-09-22
DIVIDEND Announced
Dividend - Rs 5 Per Share
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Strong Capital Efficiency: ROCE stands at 25.5%
Risks
Subject to cyclical raw material and macro industry pressures
Bull case
Market Leadership: Established operational scale in Chemicals: Agricultural.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Ownership distribution
Category trends
Hover over a period for exact holdings
Top reported holders
Largest named holdings disclosed for June 2026
Mithla Dubey
PromoterMithala Laboratories Private Limited
PromoterDhirendra Dubey
PromoterNikhil Kuber Dubey
Promoter2B Blackbio S.L. Spain
PromoterRam Kuber Dhirendra Kumar
PromoterRajesh Kumar Dubey
PromoterMadhulika Dubey
PromoterComplete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 22 Sept 2026 | Dividend | ₹5.00 / share | — | 22 Sept 2026 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 KAMA Holdings LimitedKAMAHOLD Open analysis | ₹7,245.41 | 6.63 | 0.00% | — | — | — | — |
 Kothari Industrial Corporation LimitedKOTIC Open analysis | ₹1,604.45 | — | 0.00% | ₹52.00 | -₹29.00 | +33.33% | -1,350.00% |
3B Blackbio Dx Limited3BBLACKBIO Current stock | ₹1,241.40 | 21.98 | 0.34% | ₹33.49 | ₹8.98 | +50.65% | -29.01% |
 Sharat Industries LimitedSHINDL Open analysis | ₹608.53 | 36.17 | 0.00% | ₹120.30 | ₹6.28 | +4.43% | +16.95% |
 ACS Technologies LimitedACSTECH Open analysis | ₹492.74 | 34.14 | 0.00% | ₹95.12 | ₹3.92 | +244.26% | +378.05% |
 Shree Ajit Pulp and Paper LimitedSAPPL Open analysis | ₹288.61 | 6.95 | 0.00% | ₹201.00 | ₹19.00 | +13.56% | +171.43% |
 Bilcare LimitedBI Open analysis | ₹213.46 | 27.56 | 0.00% | ₹226.00 | ₹15.00 | +21.51% | +250.00% |
 RRIL LimitedRRIL Open analysis | ₹191.88 | 19.54 | 0.00% | ₹29.49 | ₹1.76 | +22.98% | +21.38% |
Incorporated in 2011, 3B BlackBio Dx Ltd manufactures and exports PCR based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, and agrochemical-based products[1]
IndiaProcess Industries
Is 3B Blackbio Dx Limited Shariah compliant?
3B Blackbio Dx Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (0.24%) complies with AAOIFI threshold (≤ 33%).
What is 3B Blackbio Dx Limited's current valuation relative to peers?
3B Blackbio Dx Limited trades at a P/E of 22.0x compared to the sector median of 20.8x, and a Price-to-Book of 3.7x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.94x and a Net Debt to EBITDA ratio of 0.05x. Interest coverage is comfortable.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at 8.1% while net profit growth averaged 4.6%.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.